Beyond Air stock rocketed 150% on Tuesday after announcing XTL Biopharmaceuticals will acquire 85% of its NeuroNOS subsidiary. The deal values the autism and brain cancer therapeutic platform at up to $32.5 million.
XTL Biopharmaceuticals will pay 19.9% of its issued share capital plus $1 million in cash upfront. The remaining consideration includes milestone-based payments tied to clinical progress and commercial success.
The milestone structure breaks down into two categories. Clinical development payments total up to $5.5 million, triggered from Phase 1 trials through NDA submission to the FDA. Commercial milestone payments reach up to $26 million based on product sales performance.
$XAIR – Beyond Air, Inc.$XTLB – XTL Biopharmaceuticals to Acquire 85% of Beyond Air's Subsidiary NeuroNOS
For Autism with Nobel Prize-Winning Scientific Leadership
— John Zidar aka/ Stock Wizard (@JohnZidar) January 13, 2026
Beyond Air stock gained 27.85% in pre-market trading before closing up 150%. Trading volume exploded to 28 million shares compared to the three-month daily average of 6.04 million. XTL Biopharmaceuticals shares climbed 15.87% on the news.
NeuroNOS specializes in disease-modifying therapeutics for Autism Spectrum Disorder and neuro-oncology. The company’s drug platform uses proprietary small molecules engineered to cross the blood-brain barrier.
These molecules target diseases linked to nitric oxide abnormalities in the brain. Preclinical studies show the platform addresses core disease mechanisms rather than just symptoms.
Researchers have validated nitric oxide dysregulation in both autism patients and brain cancer patients. This makes nitric oxide regulation a disease-modifying therapeutic target across multiple conditions.
Current estimates show roughly one in 31 children in the U.S. are affected by Autism Spectrum Disorder. This represents a major increase that has sparked government concern. Yet no FDA-approved treatment exists for the underlying neurobiological mechanisms of the condition.
NeuroNOS has already secured two FDA Orphan Drug Designations. These cover treatments for Phelan-McDermid Syndrome and Glioblastoma.
Phelan-McDermid Syndrome is a rare genetic disorder with strong autism correlation. Glioblastoma represents an incredibly aggressive and deadly form of brain cancer.
The Orphan Drug Designations provide seven years of market exclusivity upon approval. They also offer tax credits for clinical trial costs and expedited regulatory review. Enhanced FDA engagement comes as part of the designation benefits.
Both companies stated their dedication to bringing the NeuroNOS product for autism treatment to market as quickly as possible. NeuroNOS will now serve as XTL’s flagship platform for autism and neuro-oncology therapeutics.
Beyond Air shares have rallied 20.66% year-to-date. However, the stock has fallen 87.83% over the past 12 months before Tuesday’s surge.
The deal transfers a previously wholly-owned Beyond Air subsidiary to XTL Biopharmaceuticals control. Beyond Air retains 15% ownership while gaining immediate cash and potential future milestone payments totaling up to $32.5 million.
The post Beyond Air (XAIR) Stock Soars 150% on $32M NeuroNOS Subsidiary Sale appeared first on CoinCentral.
Also read: Uniswap (UNI) Tests Key Resistance: Is a 30% Breakout Rally Imminent?
